Q-omics provides the consensus-scored CSN1S1 profile across patient tissues and cancer cell-line models. CSN1S1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, CSN1S1 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, CSN1S1 RNA expression shows 7,411 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight PAAD, BRCA, and TGCT as cancer lineages where CSN1S1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CSN1S1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CSN1S1 survival associations across molecular data types. CSN1S1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CSN1S1 RNA expression–survival associations across cancer types. High CSN1S1 expression shows unfavorable associations in ESCA, LUAD, SCLC, BRCA and UCEC, but favorable associations in PAAD. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify PAAD as the clearest survival context for CSN1S1 RNA expression.
This table summarizes CSN1S1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for CSN1S1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CSN1S1 shows lower tumor expression in BRCA, HNSC and THCA and higher tumor expression in ESCA. The BRCA box plot shows higher CSN1S1 RNA expression in normal versus tumor tissue (log2 FC = −2.257, t-test p < 0.001).
This table shows molecular features associated with CSN1S1 in patient tissues and cancer cell lines. In patient samples, CSN1S1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CSN1S1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LARGE_INTESTINE.
